Composite Lighting Spectrum to Obscure Subcutaneous Veins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lighting systems in public spaces are inadequate in preventing intravenous drug users from locating veins due to their inability to effectively inhibit the visibility of subcutaneous veins while maintaining an acceptable light quality, and existing solutions either fail to meet the Cyanosis Observation Index (COI) standards or deter users by emitting purplish blue light, which can negatively impact business establishments.
Innovation Solution
A composite lighting apparatus and method that combines narrow light emitters to produce a light source with a Cyanosis Observation Index (COI) value greater than 4.0 and a Correlated Color Temperature (CCT) between 2000° K to 50,000° K, utilizing a blueish light emitter with a peak wavelength of 440-460 nm and a yellowish light emitter with a peak wavelength of 560-585 nm, to create a perceived white light that inhibits the imaging of subcutaneous veins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a light source emits light above 580 nm wavelength to penetrate deep into skin for vein visualization, then vein visibility is improved, but the light penetrates the epidermis layer making it easy for drug users to locate veins
Solution Approach 1:
The patent changes the wavelength parameter of the light source to below 580 nm (specifically 440-460 nm blue light), which fundamentally alters the light's interaction with skin tissue. This parameter change prevents deep penetration into the dermis layer where veins are located, thereby maintaining vein invisibility for both medical practitioners and drug users.
Solution Approach 2:
The patent applies different wavelengths of light to different depths of skin tissue. By using blue light (440-460 nm), the illumination is confined to the epidermis layer only, creating a local quality effect where superficial tissue is illuminated but deeper vascular structures remain invisible.
2Object-affected harmful factors
If a light source emits purplish blue light to inhibit vein imaging, then vein locatability for drug users is reduced, but the light quality is poor and may deter public use of facilities
Solution Approach 1:
The patent uses a composite light source combining blue LED (440-460 nm) with yellow phosphor materials. This composite approach produces a perceived white light with correlated color temperature between 2000K to 50000K, maintaining good illumination quality while preserving the anti-vein-imaging properties of blue light.
Solution Approach 2:
The patent introduces yellow phosphor as an intermediary that converts some blue light into yellow light, creating a composite spectrum that appears white to the human eye. This intermediary allows the system to maintain the vein-blocking properties of blue light while improving overall light quality and color perception.
3Reliability
If a light source uses narrow bandwidth emitters to achieve specific COI and CCT values, then compliance with clinical standards is improved, but the device complexity increases
Solution Approach 1:
The patent segments the light emission into distinct wavelength components using separate LED chips (blue 440-460 nm, yellow 560-585 nm, green 500-520 nm). Each segment targets specific spectral requirements, allowing precise control over COI and CCT values while using commercially available LED components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively minimizes the ability of intravenous drug users to see veins while providing a high-quality, white light that meets the COI and CCT criteria, ensuring compliance with clinical standards and maintaining a welcoming environment for other users.
Implementation Method 1
a first narrow light emitter and a second narrow light emitter, wherein when the first narrow light emitter and the second narrow light emitter are energized then a composite light is emitted
Implementation Method 2
utilizing a blueish light emitter with a peak wavelength of 440-460 nm and a yellowish light emitter with a peak wavelength of 560-585 nm, to create a perceived white light
Implementation Method 3
it has been found that light of an appropriate wavelength must be used to irradiate the skin to penetrate enough into the skin to reach blood vessels and be reflected again to the surface
Implementation Method 4
Inside human tissues, light reflection, scattering and absorption play a role, and it has been found that scattering is the dominant factor affecting light propagation
Data Source
AI summary
A composite lighting apparatus and methods for inhibiting the optical imaging of subcutaneous veins. In an embodiment, the lighting apparatus includes a first narrow light emitter and a second narrow light emitter. When the first narrow light emitter and the second narrow light emitter are energized then a composite light is emitted that is characterized by a cyanosis observation index (COI) value of greater than four (4.0) and has a correlated color temperature (CCT) of between about 2000° K to about 50,000° K that is one of on the blackbody locus or near the blackbody locus. In some implementations, the first narrow light emitter may emit a blueish light and may have a peak wavelength in the range of about four hundred forty nanometers (440 nm) to about four hundred and sixty nanometers (460 nm). In some other embodiments, the second narrow light emitter may emit a yellowish light and may have a peak wavelength in the range of about five hundred and sixty nanometers (560 nm) to about five hundred and eighty-five nanometers (585 nm).